MOLLY K. SILKOWSKI DO , RYAN J. TEDFORD MD , JAVED BUTLER MD , BRIAN A. HOUSTON MD
{"title":"PCWL: A Compelling Hemodynamic Metric in Advancing HFpEF Diagnosis","authors":"MOLLY K. SILKOWSKI DO , RYAN J. TEDFORD MD , JAVED BUTLER MD , BRIAN A. HOUSTON MD","doi":"10.1016/j.cardfail.2025.02.005","DOIUrl":"10.1016/j.cardfail.2025.02.005","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 845-847"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ELENA M. DONALD MD , ALEXANDER G. HAJDUCZOK MD , RACHEL GOODMAN MD , SHAZLI KHAN MD , DANIEL BURKHOFF MD, PhD , ADITI NAYAK MD
{"title":"Innovate and Translate: Highlights From Technology and Heart Failure Therapeutics, 2025, in Boston","authors":"ELENA M. DONALD MD , ALEXANDER G. HAJDUCZOK MD , RACHEL GOODMAN MD , SHAZLI KHAN MD , DANIEL BURKHOFF MD, PhD , ADITI NAYAK MD","doi":"10.1016/j.cardfail.2025.02.012","DOIUrl":"10.1016/j.cardfail.2025.02.012","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 848-852"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MARIA GAMERO MD , ESTEFANIA OLIVEROS SOLES MD, MSc , YEVGENIY BRAILOVSKY DO, MSc
{"title":"Is Simpler Better? The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Cardiomyopathy","authors":"MARIA GAMERO MD , ESTEFANIA OLIVEROS SOLES MD, MSc , YEVGENIY BRAILOVSKY DO, MSc","doi":"10.1016/j.cardfail.2025.03.007","DOIUrl":"10.1016/j.cardfail.2025.03.007","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 821-823"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
SHANA D.R. LITTLETON BS , DAVID E. LANFEAR MD, MS , MICHAEL P. DORSCH PharmD, MS , BIN LIU PhD, MPH , JASMINE A. LUZUM PharmD, PhD
{"title":"Equal Treatment, Unequal Outcomes? Debunking the Racial Disparity in Renin Angiotensin Aldosterone System Inhibitor–Associated Reduction in Heart Failure Hospitalizations","authors":"SHANA D.R. LITTLETON BS , DAVID E. LANFEAR MD, MS , MICHAEL P. DORSCH PharmD, MS , BIN LIU PhD, MPH , JASMINE A. LUZUM PharmD, PhD","doi":"10.1016/j.cardfail.2024.09.012","DOIUrl":"10.1016/j.cardfail.2024.09.012","url":null,"abstract":"<div><h3>Background</h3><div>Renin angiotensin aldosterone system inhibitors (RAASi) are a mainstay treatment in patients with heart failure with reduced ejection fraction (HFrEF) in part to prevent hospitalizations. However, whether RAASi reduce the risk of hospitalization in Black patients is not entirely clear because enrollment of Black patients in previous clinical trials was low and a previous meta-analysis showed a significant racial disparity: reduction in hospitalizations with an RAASi in White patients but not Black patients. Previous studies relied on the use of self-identified race instead of genomic ancestry. Therefore, this study aimed to investigate the role of self-identified race and genomic ancestry in the racial disparity in RAASi–associated reductions in HFrEF hospitalizations.</div></div><div><h3>Methods</h3><div>The primary outcome was time to first heart failure hospitalization. Data from the Henry Ford Heart Failure Pharmacogenomic Registry (HFPGR) and the GUIDE-IT multi-center randomized control trial were analyzed with Cox proportional hazards models un/adjusted for clinical risk factors, death as a competing risk, and time-varying RAASi exposure. The proportion of Yoruba African ancestry was quantified. Analyses of self-identified race were performed in both the HFPGR and GUIDE-IT. Analysis of genomic ancestry was only performed in the HFPGR since this information was not available in GUIDE-IT. A fixed effect meta-analysis combined results of both the HFPGR and GUIDE-IT for race.</div></div><div><h3>Results</h3><div>The HFPGR had 1010 total HFrEF patients (Black = 509 and White = 501) with 852 having ancestry quantification (>80% Yoruba African Ancestry = 381 and <5% Yoruba African Ancestry = 471). GUIDE-IT had 810 HFrEF patients (Black = 322 and White = 488). There was no significant difference in the association of RAASi exposure with heart failure hospitalization by race (meta-analysis <em>P</em> value for race*RAASi exposure interaction = .49; Black patients hazard ratio [HR, 95% confidence interval] for RAASi exposure = 0.89 [0.64–1.23)], <em>P</em> = .47; White patients = 1.20 [0.83–1.75], <em>P</em> = .34). Results were similar when analyzed by ancestry (<em>P</em> value for ancestry*RAASi exposure interaction = 0.57; >80% Yoruba African Ancestry = 0.93 [0.51–1.69], <em>P</em> = .80; <5% Yoruba African Ancestry = 1.29 [0.57–2.92], <em>P</em> = .54).</div></div><div><h3>Conclusions</h3><div>In contrast to a previous meta-analysis, this more contemporary analysis of 2 HFrEF patient datasets demonstrates the absence of a racial disparity in RAASi–associated reductions in heart failure hospitalizations. The difference in this racial disparity over time may be due to improvements in background heart failure therapies, racial differences in health care usage, and the use of more advanced statistical approaches.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 800-809"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
EDAN ZITELNY MD , MARK H. DRAZNER MD, MSc , JONATHAN DAVIS MD , NOSHEEN REZA MD , ERSILIA M. DEFILIPPIS MD , PRATEETI KHAZANIE MD, MPH , JOHN R. TEERLINK MD , RACHNA KATARIA MD
{"title":"ExCITe: A Narrative Review of Motivating Factors for Residency and Fellowship Selection to Provide Insights Regarding the Waning Interest in Advanced Heart Failure and Transplant Cardiology Training","authors":"EDAN ZITELNY MD , MARK H. DRAZNER MD, MSc , JONATHAN DAVIS MD , NOSHEEN REZA MD , ERSILIA M. DEFILIPPIS MD , PRATEETI KHAZANIE MD, MPH , JOHN R. TEERLINK MD , RACHNA KATARIA MD","doi":"10.1016/j.cardfail.2024.10.443","DOIUrl":"10.1016/j.cardfail.2024.10.443","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 853-857"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Novel Predictive Score Model for Successful Weaning From Mechanical Circulatory Support in Patients With Cardiogenic Shock","authors":"SHO SUZUKI MD , NAMI TERAOKA MD , KII ITO MD , YUKARI OKUMA MD , KAZUHIRO KIMURA MD , MASATOSHI MINAMISAWA MD , SOICHIRO EBISAWA MD , HIROHIKO MOTOKI MD , HIROSHI IMAMURA MD , TATSUICHIRO SETO MD , KOICHIRO KUWAHARA MD","doi":"10.1016/j.cardfail.2024.07.023","DOIUrl":"10.1016/j.cardfail.2024.07.023","url":null,"abstract":"<div><h3>Background</h3><div>Clinical evidence regarding predictors of successful weaning from mechanical circulatory support (MCS) is lacking. This study aimed to create a simple risk score to predict successful weaning from MCS in patients with cardiogenic shock.</div></div><div><h3>Methods and Results</h3><div>This retrospective single-center cohort study included 114 consecutive patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation or IMPELLA between January 2013 and June 2023. Patients with out-of-hospital cardiac arrest were excluded. The primary end point was successful weaning from MCS, defined as successful decannulation without the need for MCS reimplantation and survival to discharge. Multivariable logistic regression with a stepwise variable selection was performed to generate the prediction model. We first developed a general weaning score model, and then created a simple version of the score model using the same variables. Fifty-five patients were weaned from MCS successfully. The following variables measured during weaning evaluation were selected as the components of the weaning score model: acute myocardial infarction (AMI), mean blood pressure, left ventricular ejection fraction (LVEF), lactate level, and QRS duration. According to the results, we conducted a novel weaning score model to predict successful weaning from MCS: 1.774 – 2.090 × (AMI) + 0.062 × [mean blood pressure (mm Hg)] + 0.139 × [LVEF (%)] – 0.322 × [Lactate (mg/dL)] – 0.066 × [QRS (ms)]. The following variables were selected as the components of the simple version of the weaning score model: AMI, mean blood pressure of ≥80 mm Hg, lactate of <10 mg/dL, QRS duration of ≤95 ms, and LVEF of >35%.</div></div><div><h3>Conclusions</h3><div>We developed a simple model to predict successful weaning from MCS in patients with cardiogenic shock.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 791-799"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prevalence and Prognostic Implications of Changes in Tricuspid Regurgitation Severity in Acute Heart Failure","authors":"TETSUYA KOBAYASHI MD , YUYA MATSUE MD, PhD , YUDAI FUJIMOTO MD , DAICHI MAEDA MD, PhD , KEISUKE KIDA MD, PhD , TAKESHI KITAI MD, PhD , NOBUYUKI KAGIYAMA MD, PhD , TETSUO YAMAGUCHI MD, PhD , TAKAHIRO OKUMURA MD, PhD , ATSUSHI MIZUNO MD , SHOGO OISHI MD , YASUTAKA INUZUKA MD, PhD , EIICHI AKIYAMA MD , SATOSHI SUZUKI MD, PhD , MASAYOSHI YAMAMOTO MD, PhD , YUICHI TAMURA MD, PhD , TOHRU MINAMINO MD, PhD","doi":"10.1016/j.cardfail.2024.08.043","DOIUrl":"10.1016/j.cardfail.2024.08.043","url":null,"abstract":"<div><h3>Background</h3><div>Tricuspid regurgitation (TR), prevalent in acute heart failure (AHF), has a poor prognosis; however, the dynamics of TR severity during hospitalization and its prognostic implications remain unclear. We investigated TR dynamism during hospitalization and its prognostic impact in AHF.</div></div><div><h3>Methods and Results</h3><div>This is a post hoc analysis of a prospective multicenter study of patients with AHF who underwent echocardiographic TR severity evaluation at admission and before discharge. The primary end point was a combined of 1-year all-cause mortality and HF rehospitalization after discharge. Among 1079 participants, TR severity changed dynamically, with 60.3% of those with moderate TR and 29.6% of those with severe TR at admission being diagnosed as no or mild TR at discharge. In 3 groups stratified by changes in TR severity, the persistent TR groups had a higher incidence of the primary end point than the resolution and absence groups. In adjusted analyses, the persistent group (hazard ratio, 1.37; 95% confidence interval, 1.04–1.80), but not the resolution group (hazard ratio, 1.07; 95% confidence interval, 0.79–1.44), had a higher primary end point incidence than the absence group.</div></div><div><h3>Conclusions</h3><div>TR severity at admission in patients with AHF can change dynamically and is associated with subsequent prognosis. Significant TR that remains even after decongestive therapy might be a target for further treatment in hospitalized patients with AHF.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"31 5","pages":"Pages 781-788"},"PeriodicalIF":6.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}